Differential Treatment Response Between Hypochondriasis With and Without Prominent Somatic Symptoms

Area of Science:

• Psychiatry
• Clinical Psychology
• Medical Research

Background:

• Health anxiety (hypochondriasis) can present with or without significant somatic symptoms.
• The impact of somatic symptom burden on treatment effectiveness for health anxiety remains unclear.
• Symptom burden may influence the optimal choice of therapeutic interventions.

Purpose of the Study:

• To investigate how somatic symptom burden affects treatment response in individuals with hypochondriasis.
• To determine if symptom burden influences the efficacy of different treatment modalities.

Main Methods:

• Exploratory study utilizing data from a randomized controlled trial of 193 individuals with DSM-IV hypochondriasis.
• Participants were assigned to cognitive behavioral therapy, fluoxetine, combined therapy, or placebo.
• Subgroups were defined by somatic symptom burden: no/low (n=42) and prominent (n=151). Treatment response was defined as ≥30% improvement in hypochondriasis symptoms.

Main Results:

• Among participants with high somatic burden, fluoxetine (alone or combined with CBT) significantly increased odds of response compared to placebo.
• Among participants with low somatic burden, cognitive behavioral therapy (alone or combined with fluoxetine) showed higher odds of response compared to placebo.
• High somatic burden individuals receiving any fluoxetine had greater odds of response than those not receiving fluoxetine; low somatic burden individuals receiving any CBT had greater odds of response than those not receiving CBT.

Conclusions:

• Somatic symptom burden is a crucial factor in guiding treatment selection for individuals with significant health anxiety.
• Individuals with high somatic burden in hypochondriasis may respond better to fluoxetine.
• Individuals with low somatic burden may achieve better outcomes with cognitive behavioral therapy, warranting further research.